Bayer Outlines Asundexian Phase III Plan, Hoping To Prove Safety Benefit Over Eliquis

 
• By Jessica Merrill

The Factor XIa inhibitor could be an effective anticoagulant without the increased risk in bleeding associated with current Factor Xa inhibitors, but the profile will need to be confirmed in Phase III.

Risk Sign
Bayer is looking to develop a oral anticoagulant with fewer bleeding risks • Source: Shutterstock

More from Blood and Clotting

More from Therapy Areas